治疗成人中重度急性疼痛新药oliceridine  

Oliceridine:a new drug for the treatment of moderate to severe acute pain in adults

作　　者：吴禧敏 张晓静 冯汨 常惠礼[1] WU Xi-min;ZHANG Xiao-jing;FENG Mi;CHANG Hui-li(The Sixth Affiliated Hospital of Guangzhou Medical University,Qingyuan 511500,China)

机构地区：[1]广州医科大学附属第六医院,清远511500

出　　处：《中国新药杂志》2023年第5期469-475,共7页Chinese Journal of New Drugs

摘　　要：oliceridine是一种对G蛋白通路具有偏向性的新型阿片μ受体激动剂。2020年8月7日,美国FDA批准oliceridine用于静脉注射治疗成人中重度急性疼痛。临床研究显示,oliceridine有不劣于吗啡的良好镇痛功效,同时降低了传统阿片类药物不良反应(opioid-related adverse events,ORAEs)的发生风险。现对oliceridine的作用机制、药动学、药效学、临床研究、安全性评价等进行概述。Oliceridine is a G-protein-biasedμ-opioid receptor agonist.It was approved by the U.S.FDA for the treatment of moderate to severe acute pain in adults by intravenous injection on August 7,2020.Clinical studies have shown that oliceridine has a favorable analgesic efficacy which is noninferior than morphine with a lower risk of opioid-related adverse events than conventional opioids at the same time.This review focuses on the mechanism of action,pharmacokinetics,pharmacodynamics,clinical studies and safety evaluation of oliceridine.

关 键 词：oliceridine 中重度急性疼痛 阿片μ受体激动剂 G蛋白偏向性激动剂 

分 类 号：R969.4[医药卫生—药理学]